CCM
CHRS icon

Cadence Capital Management’s Coherus Oncology CHRS Stock Holding History

Cadence Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$493K Sell
26,900
-88,409
-77% -$1.64M 0.12% 138
2020
Q2 		$2.06M Buy
115,309
+4,815
+4% +$81.5K 0.3% 77
2020
Q1 		$1.79M Sell
110,494
-5,718
-5% -$106K 0.3% 77
2019
Q4 		$2.09M Sell
116,212
-13,780
-11% -$254K 0.23% 120
2019
Q3 		$2.63M Buy
+129,992
New +$2.6M 0.37% 81

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Cadence Capital Management's CHRS Position: Q3 2020 in Review

Cadence Capital Management reduced its Coherus Oncology (CHRS) stake by 77% in Q3 2020, selling an estimated $1.64M and leaving 26,900 shares worth $493K. The position accounts for 0.12% of the portfolio, ranked #138.

Cadence Capital Management first reported a position in CHRS in Q3 2019 and has held it in 5 quarters since. The position peaked at $2.63M in Q3 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

  • Cadence Capital Management held 26,900 shares of Coherus Oncology worth $493K as of Q3 2020.
  • Cadence Capital Management sold 88,409 Coherus Oncology shares in Q3 2020, an estimated $1.64M.
  • Coherus Oncology made up 0.12% of Cadence Capital Management's portfolio in Q3 2020, its #138 holding.
  • Cadence Capital Management first reported a position in Coherus Oncology in Q3 2019 and has held it in 5 quarters since.
  • Cadence Capital Management's Coherus Oncology position peaked at $2.63M in Q3 2019.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.